To help strengthen global collaboration and showcase innovative biotics research, The International Scientific Association for Probiotics and Prebiotics (ISAPP) is organizing a scientific symposium on October 6, 2026 in Tokyo, Japan in conjunction with its annual meeting. The event will bring together leading academic and industry experts in biotic science from North and South America, Europe, Australasia, and across Asia, all coming together for an exciting day of networking, discussion and knowledge-sharing.

This four-paper Series and accompanying comments examine the growing but under-recognised burden of chronic liver disease in Europe, with a focus on steatotic liver disease, including metabolic dysfunction-associated steatotic liver disease, and alcohol-related liver disease, along with viral hepatitis B and C. The Series provides country-level data on MASLD policies, analyses systemic failures in prevention, timely detection, and equitable access to care across diverse populations and health systems; and evaluates policy gaps, health system responses, and innovations in diagnostics, care models, and public health strategies. The Series calls for the rapid integration of metabolic liver health into non-communicable disease frameworks, strengthened surveillance and care pathways, and coordinated, equity-driven, and preventative approaches to identify the “missing millions” and reduce the rising human and economic toll of chronic liver disease across the region.

A report analyzed the frequency and magnitude of savings from purchasing generic prescriptions through the Mark Cuban Cost Plus Drug Company (MCCPDC) compared with cost sharing under employer-sponsored insurance.

Researchers have discovered how part of the body’s immune system could better combat a leading cause of death for people with cystic fibrosis (CF).

A team led by The University of Queensland's Professor Peter Sly and Dr Abdullah Tarique has identified how macrophages – the white blood cells that fight infection in the body – function differently in people with CF, compared to others.